Mystery drug combo promises to reverse aging, startup says
Generation Lab, founded by parabiosis researcher Irina Conboy, claims its injectable combination of two existing drugs can block aging spread and restore tissue youth, but it has not disclosed the drug names. The company invited a MIT Technology Review reporter to join a private cohort, citing a celebrity waitlist, while offering no scientific evidence. The lack of transparency and reliance on influencer marketing raise doubts about the treatment's credibility.
Generation Lab’s treatment combines two undisclosed existing drugs, administered by injection, and is being positioned as a first-of-its-kind longevity therapeutic. The company’s founder, Irina Conboy, has a background in parabiosis research, where joining the blood systems of young and old animals shows rejuvenating effects. The startup is now recruiting a small “private cohort” of influencers and celebrities, while planning a larger study led by alternative-medicine practitioners with a history of promoting unproven therapies. No peer-reviewed data or drug names have been released.
The pitch to a technology reporter included anecdotal claims of improved vision, stamina, and sexual function, but no controlled evidence. The company’s reliance on influencer marketing and its refusal to disclose the drug identities underscore the gap between bold promises and scientific verification. This pattern mirrors broader trends in the longevity sector, where hype often outpaces rigorous clinical validation.
If this treatment gains traction, it could reshape consumer expectations around aging, pushing people toward unregulated injectables before safety and efficacy are established. The celebrity waitlist and influencer outreach may create social pressure to try the therapy, particularly among affluent, health-conscious individuals. However, the lack of transparency could erode public trust in legitimate longevity research, making it harder for credible scientists to distinguish real breakthroughs from marketing stunts. Regulators and physicians may face increased demand for oversight of such direct-to-consumer offerings.